Brought to you by 
Astellas pays Aveo $125mm up front for rights to tivozanib; deal terminated
08 Dec 2015
Executive Summary
Astellas Pharma Inc. has licensed exclusive worldwide rights outside of Asia to develop, manufacture, and sell oncology company's Aveo Pharmaceuticals Inc.’s Phase III cancer compound tivozanib. The Japanese pharmaco paid $125mm up front, a fee that includes $50mm for ongoing R&D.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas pays Aveo $125mm up front for rights to tivozanib; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice